Capital Performance Advisors LLP Biotechnology

Capital Performance Advisors LLP

$325 Million
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ALNY Alnylam Pharmaceuticals, Inc.	$28.7B	$121,000 0.04% of portfolio	440	Q3 2024 New
RARE Ultragenyx Pharmaceutical Inc.	$2.99B	$107,000 0.03% of portfolio	1,934	Q3 2024 New
UTHR United Therapeutics Corp	$16.2B	$82,000 0.03% of portfolio	229	Q3 2024 New
OCUL Ocular Therapeutix, Inc	$683M	$69,000 0.02% of portfolio	8,034	Q3 2024 New
EXEL Exelixis, Inc.	$10.7B	$61,000 0.02% of portfolio	2,358	Q3 2024 New
APLS Apellis Pharmaceuticals, Inc.	$3.78B	$56,000 0.02% of portfolio	1,944	Q3 2024 New
INCY Incyte Corp	$16B	$45,000 0.01% of portfolio	686	Q3 2024 New
NVO Novo Nordisk A S	$192B	$41,000 0.01% of portfolio	350	Q3 2024 New
IONS Ionis Pharmaceuticals Inc	$4.84B	$40,000 0.01% of portfolio	1,000	Q3 2024 New
VRTX Vertex Pharmaceuticals Inc	$103B	$38,000 0.01% of portfolio	83	Q3 2024 New
PLX Protalix Bio Therapeutics, Inc.	$105M	$26,000 0.01% of portfolio	25,976	Q3 2024 Reduced 3.05%
CORT Corcept Therapeutics Inc	$5.53B	$24,000 0.01% of portfolio	538	Q3 2024 New
ADMA Adma Biologics, Inc.	$3.76B	$18,000 0.01% of portfolio	949	Q3 2024 New
REGN Regeneron Pharmaceuticals, Inc.	$76.8B	$13,000 0.0% of portfolio	13	Q3 2024 New
PTCT Ptc Therapeutics, Inc.	$3.28B	$13,000 0.0% of portfolio	373	Q3 2024 New
CPRX Catalyst Pharmaceuticals, Inc.	$2.08B	$12,000 0.0% of portfolio	646	Q3 2024 New
BCRX Biocryst Pharmaceuticals Inc	$1.46B	$11,000 0.0% of portfolio	1,512	Q3 2024 New
BMRN Biomarin Pharmaceutical Inc	$12.5B	$11,000 0.0% of portfolio	168	Q3 2024 New
ROIV Roivant Sciences Ltd.	$8.11B	$11,000 0.0% of portfolio	1,000	Q3 2024 New
QURE Uni Qure N.V.	$845M	$10,000 0.0% of portfolio	2,180	Q3 2024 New
AUPH Aurinia Pharmaceuticals Inc.	$1.19B	$8,000 0.0% of portfolio	1,181	Q3 2024 New
VCYT Veracyte, Inc.	$3.11B	$8,000 0.0% of portfolio	259	Q3 2024 New
VKTX Viking Therapeutics, Inc.	$3.26B	$8,000 0.0% of portfolio	128	Q3 2024 New
ANNX Annexon, Inc.	$240M	$8,000 0.0% of portfolio	1,438	Q3 2024 New
ARDX Ardelyx, Inc.	$787M	$7,000 0.0% of portfolio	1,064	Q3 2024 New
TVTX Travere Therapeutics, Inc.	$1.2B	$6,000 0.0% of portfolio	458	Q3 2024 New
AGIO Agios Pharmaceuticals, Inc.	$1.84B	$6,000 0.0% of portfolio	155	Q3 2024 New
ARQT Arcutis Biotherapeutics, Inc.	$885M	$6,000 0.0% of portfolio	728	Q3 2024 New
APLT Applied Therapeutics Inc.	$45.1M	$5,000 0.0% of portfolio	677	Q3 2024 New
BBIO Bridge Bio Pharma, Inc.	$4.19B	$5,000 0.0% of portfolio	222	Q3 2024 New
MGNX Macrogenics Inc	$214M	$4,000 0.0% of portfolio	1,462	Q3 2024 New
PTGX Protagonist Therapeutics, Inc	$1.87B	$3,000 0.0% of portfolio	79	Q3 2024 New
HALO Halozyme Therapeutics, Inc.	$7.04B	$3,000 0.0% of portfolio	59	Q3 2024 New
SAGE Sage Therapeutics, Inc.	$370M	$3,000 0.0% of portfolio	502	Q3 2024 New
BPMC Blueprint Medicines Corp	$5.35B	$3,000 0.0% of portfolio	41	Q3 2024 New
STRO Sutro Biopharma, Inc.	$106M	$3,000 0.0% of portfolio	896	Q3 2024 New
ADPT Adaptive Biotechnologies Corp	$1.01B	$3,000 0.0% of portfolio	764	Q3 2024 New
HRMY Harmony Biosciences Holdings, Inc.	$2.04B	$3,000 0.0% of portfolio	84	Q3 2024 New
TECH Bio Techne Corp	$2.91B	$2,000 0.0% of portfolio	35	Q3 2024 New
HRTX Heron Therapeutics, Inc.	$213M	$2,000 0.0% of portfolio	1,242	Q3 2024 New
SRPT Sarepta Therapeutics, Inc.	$11.2B	$2,000 0.0% of portfolio	17	Q3 2024 New
ABUS Arbutus Biopharma Corp	$490M	$2,000 0.0% of portfolio	545	Q3 2024 New
JAZZ Jazz Pharmaceuticals PLC	$7.64B	$2,000 0.0% of portfolio	24	Q3 2024 New
CHRS Coherus Bio Sciences, Inc.	$126M	$2,000 0.0% of portfolio	2,117	Q3 2024 New
KURA Kura Oncology, Inc.	$569M	$2,000 0.0% of portfolio	147	Q3 2024 New
EDIT Editas Medicine, Inc.	$98.3M	$2,000 0.0% of portfolio	761	Q3 2024 New
NTLA Intellia Therapeutics, Inc.	$973M	$2,000 0.0% of portfolio	106	Q3 2024 New
DYN Dyne Therapeutics, Inc.	$1.27B	$2,000 0.0% of portfolio	81	Q3 2024 New
LGND Ligand Pharmaceuticals Inc	$1.82B	$1,000 0.0% of portfolio	17	Q3 2024 New
INSM Insmed Inc	$9.03B	$1,000 0.0% of portfolio	23	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.